eGFR- and Potassium-Guided Stewardship of SGLT2 Inhibitors and Finerenone in Albuminuric Chronic Kidney Disease Associated with Type 2 Diabetes. (PubMed, Diabetes Metab Syndr Obes) - Sep 16, 2026 - "The Phase 2, randomized, double-blind Combination Effect of Finerenone and Empagliflozin in Participants with Chronic Kidney Disease and Type 2 Diabetes Using a Urinary Albumin-to-Creatinine Ratio Endpoint (CONFIDENCE) trial subsequently showed that simultaneous finerenone-empagliflozin initiation produced greater short-term albuminuria reduction than either monotherapy, but this biomarker benefit does not establish hard-outcome superiority or define the optimal sequencing strategy. Simultaneous initiation may be appropriate in patients with persistent albuminuria, stable eGFR, normal or low-normal potassium, and reliable monitoring access, whereas sequential initiation is often more suitable when potassium risk, hemodynamic instability, or follow-up uncertainty is present. Future studies should move beyond short-term urine albumin-to-creatinine ratio (UACR) lowering to evaluate clinical kidney and cardiovascular outcomes, treatment persistence, potassium-event..."
Clinical • Journal • Review • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Fibrosis • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus
|
|
Chen Su; Dan Liu; Shuang Wang; Xumin Li
|